{"filing":{"accession_number":"0001376339-26-000074","cik":"0001376339","ticker":"MDXG","company_name":"MIMEDX GROUP, INC.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"mdxg-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1376339/000137633926000074/mdxg-20260729.htm"},"events":[{"id":21614,"run_id":19498,"accession_number":"0001376339-26-000074","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"MiMedx issued a press release on July 29, 2026 announcing second quarter 2026 financial results, including net sales of $64 million (down 35% year-over-year), a net loss of $15 million (versus net income of $10 million in Q2 2025), and gross margin compression from 81% to 69%.","company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21297,"accession_number":"0001376339-26-000074","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MiMedx issued a press release on July 29, 2026 announcing second quarter 2026 financial results, including net sales of $64 million (down 35% year-over-year), a net loss of $15 million (versus net income of $10 million in Q2 2025), and gross margin compression from 81% to 69%. The filing explicitly states this is furnished pursuant to Item 2.02 \"Results of Operations and Financial Condition\" with the earnings press release attached as Exhibit 99.1. The disclosure of quarterly operating and financial results is a classic earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:13:42.296188+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21298,"accession_number":"0001376339-26-000074","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 7.01 disclosure announces a conference call to discuss Q2 2026 financial and operating results, with supporting slide presentations furnished as exhibits. The attached press release (EX-99.1) reports Q2 net sales of $64 million (down 35% YoY), a net loss of $15 million, and announces a material acquisition of Sanara MedTech. While Item 7.01 is technically \"Other Events,\" the core disclosure is the earnings announcement and results discussion, making earnings_release the primary event type. The M\u0026A activity is secondary to the earnings disclosure in this Item.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:13:42.296188+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21297,"accession_number":"0001376339-26-000074","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MiMedx issued a press release on July 29, 2026 announcing second quarter 2026 financial results, including net sales of $64 million (down 35% year-over-year), a net loss of $15 million (versus net income of $10 million in Q2 2025), and gross margin compression from 81% to 69%. The filing explicitly states this is furnished pursuant to Item 2.02 \"Results of Operations and Financial Condition\" with the earnings press release attached as Exhibit 99.1. The disclosure of quarterly operating and financial results is a classic earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:13:42.296188+00:00","company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","filing_date":"2026-07-29"},{"id":21298,"accession_number":"0001376339-26-000074","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 7.01 disclosure announces a conference call to discuss Q2 2026 financial and operating results, with supporting slide presentations furnished as exhibits. The attached press release (EX-99.1) reports Q2 net sales of $64 million (down 35% YoY), a net loss of $15 million, and announces a material acquisition of Sanara MedTech. While Item 7.01 is technically \"Other Events,\" the core disclosure is the earnings announcement and results discussion, making earnings_release the primary event type. The M\u0026A activity is secondary to the earnings disclosure in this Item.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:13:42.296188+00:00","company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","filing_date":"2026-07-29"}]}